Cargando…

Comprehensive description of adult-onset Still's disease after COVID-19 vaccination

Cases of adult-onset Still's disease (AOSD) have been reported after COVID-19 vaccination. Here we provide a comprehensive description and analysis of all cases of AOSD reported in the literature and in pharmacovigilance databases through April 2022. Disproportionality analyses of pharmacovigil...

Descripción completa

Detalles Bibliográficos
Autores principales: Palassin, Pascale, Bres, Virginie, Hassan, Samaher, Alfonsi, Ange, Massy, Nathalie, Gras-Champel, Valérie, Maria, Alexandre Thibault Jacques, Faillie, Jean-Luc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755011/
https://www.ncbi.nlm.nih.gov/pubmed/36592513
http://dx.doi.org/10.1016/j.jaut.2022.102980
_version_ 1784851333458690048
author Palassin, Pascale
Bres, Virginie
Hassan, Samaher
Alfonsi, Ange
Massy, Nathalie
Gras-Champel, Valérie
Maria, Alexandre Thibault Jacques
Faillie, Jean-Luc
author_facet Palassin, Pascale
Bres, Virginie
Hassan, Samaher
Alfonsi, Ange
Massy, Nathalie
Gras-Champel, Valérie
Maria, Alexandre Thibault Jacques
Faillie, Jean-Luc
author_sort Palassin, Pascale
collection PubMed
description Cases of adult-onset Still's disease (AOSD) have been reported after COVID-19 vaccination. Here we provide a comprehensive description and analysis of all cases of AOSD reported in the literature and in pharmacovigilance databases through April 2022. Disproportionality analyses of pharmacovigilance data were performed in order to further explore the association between vaccination and AOSD. We included 159 patients, 144 from the World Health Organization pharmacovigilance database and 15 from the literature. Detailed clinical characteristics were described for the cases from the literature and from the French pharmacovigilance database (n = 9). The cases of AOSD after COVID-19 vaccination concerned women in 52.2% of cases. The median age was 43.4 years. More than 80% of AOSD reports occurred during the first three weeks and concerned mostly the BNT162b2 mRNA vaccine. We identified 14.5% of disease flare with a median time-to-onset of AOSD flare-up significantly shorter than for the new onset form. More than 90% patients received steroids. Although all cases were considered serious and required hospitalization, most cases presented a favorable outcome (67.1%) with a good response to corticosteroid therapy with a mean time to recovery of 7.2 days. Disproportionality analyses suggested that AOSD was associated with COVID-19 vaccines as well as other vaccines. AOSD was nearly five times more frequently reported with COVID-19 vaccines than with all other drugs. Clinicians should be informed about the potential risk of AOSD onset or flare following COVID vaccines and the importance of its early detection to optimize its management.
format Online
Article
Text
id pubmed-9755011
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-97550112022-12-16 Comprehensive description of adult-onset Still's disease after COVID-19 vaccination Palassin, Pascale Bres, Virginie Hassan, Samaher Alfonsi, Ange Massy, Nathalie Gras-Champel, Valérie Maria, Alexandre Thibault Jacques Faillie, Jean-Luc J Autoimmun Article Cases of adult-onset Still's disease (AOSD) have been reported after COVID-19 vaccination. Here we provide a comprehensive description and analysis of all cases of AOSD reported in the literature and in pharmacovigilance databases through April 2022. Disproportionality analyses of pharmacovigilance data were performed in order to further explore the association between vaccination and AOSD. We included 159 patients, 144 from the World Health Organization pharmacovigilance database and 15 from the literature. Detailed clinical characteristics were described for the cases from the literature and from the French pharmacovigilance database (n = 9). The cases of AOSD after COVID-19 vaccination concerned women in 52.2% of cases. The median age was 43.4 years. More than 80% of AOSD reports occurred during the first three weeks and concerned mostly the BNT162b2 mRNA vaccine. We identified 14.5% of disease flare with a median time-to-onset of AOSD flare-up significantly shorter than for the new onset form. More than 90% patients received steroids. Although all cases were considered serious and required hospitalization, most cases presented a favorable outcome (67.1%) with a good response to corticosteroid therapy with a mean time to recovery of 7.2 days. Disproportionality analyses suggested that AOSD was associated with COVID-19 vaccines as well as other vaccines. AOSD was nearly five times more frequently reported with COVID-19 vaccines than with all other drugs. Clinicians should be informed about the potential risk of AOSD onset or flare following COVID vaccines and the importance of its early detection to optimize its management. Elsevier Ltd. 2023-01 2022-12-16 /pmc/articles/PMC9755011/ /pubmed/36592513 http://dx.doi.org/10.1016/j.jaut.2022.102980 Text en © 2022 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Palassin, Pascale
Bres, Virginie
Hassan, Samaher
Alfonsi, Ange
Massy, Nathalie
Gras-Champel, Valérie
Maria, Alexandre Thibault Jacques
Faillie, Jean-Luc
Comprehensive description of adult-onset Still's disease after COVID-19 vaccination
title Comprehensive description of adult-onset Still's disease after COVID-19 vaccination
title_full Comprehensive description of adult-onset Still's disease after COVID-19 vaccination
title_fullStr Comprehensive description of adult-onset Still's disease after COVID-19 vaccination
title_full_unstemmed Comprehensive description of adult-onset Still's disease after COVID-19 vaccination
title_short Comprehensive description of adult-onset Still's disease after COVID-19 vaccination
title_sort comprehensive description of adult-onset still's disease after covid-19 vaccination
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9755011/
https://www.ncbi.nlm.nih.gov/pubmed/36592513
http://dx.doi.org/10.1016/j.jaut.2022.102980
work_keys_str_mv AT palassinpascale comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination
AT bresvirginie comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination
AT hassansamaher comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination
AT alfonsiange comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination
AT massynathalie comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination
AT graschampelvalerie comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination
AT mariaalexandrethibaultjacques comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination
AT failliejeanluc comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination
AT comprehensivedescriptionofadultonsetstillsdiseaseaftercovid19vaccination